After completing a Priority Review, the U.S. FDA has approved Mulpleta (lusutrombopag), a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. “We are very pleased the FDA has approved Mulpleta as a new, safe, and effective…